Nonclinical safety profiles of DS-1515, a novel oral PI3Kd inhibitor. Source: International Congress 2018 – Basic pharmacology Year: 2018
In vitro pharmacological profile of SMP-028, a novel potent anti-inflammatory agentSource: Annual Congress 2010 - Models of airways disease Year: 2010
Comparison of the efficacy and safety of 5 different doses of the novel very long acting β2-agonist carmoterol Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006
Preclinical anti-inflammatory activity and safety profile of the novel glucocorticoid ciclesonide Source: Eur Respir J 2001; 18: Suppl. 33, 147s Year: 2001
Pharmacological properties of a novel PI3Kd inhibitor, DS-1515 Source: International Congress 2018 – Basic pharmacology Year: 2018
Bronchoprotective activity and safety evaluation of the novel antimuscarinic/ß2 agonist (MABA) CHF6366 in dogs Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
ADME properties of a novel PI3Kd inhibitor, DS-1515, in preclinical studies Source: International Congress 2018 – Basic pharmacology Year: 2018
Roflumilast, a selective phosphodiesterase 4 inhibitor, shows efficacy and safety in the long-term treatment of asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Aclidinium bromide, a novel long-acting anticholinergic drug, has a good preclinical cardiovascular safety profile Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008
Safety profile of a novel peptide,PIN201104,with potential to act as a disease modifying,broad spectrum treatment for asthma Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018
Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in COPD Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
In vitro pharmacological characterization of the potent, lung selective pan-JAK inhibitor TD-8236 Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019
AWD 12-281, a new selective PDE4-inhibitor with a high safety margin: separation of anti-inflammatory and emetic effects in ferrets and domestic pigs Source: Eur Respir J 2002; 20: Suppl. 38, 617s Year: 2002
The bronchodilatory and anti-inflammatory effect of MT-810, a novel selective phosphodiesterase-4 (PDE4) inhibitor Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006
How to disrupt malicious LC-fILD pathways: antifibrotic agents as a promising therapeutic approach Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021
The safety, tolerability and pharmacokinetics of AZD5069, a novel CXCR2 antagonist, in healthy Japanese volunteers Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012
In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systemsSource: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
In vitro pharmacological characterization of a novel p38α (MAPK14) inhibitor designed for inhaled delivery Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
A randomized, crossover study to examine the pharmacodynamics and safety of a new antimuscarinic (TD-4208) in COPD Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012